Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes

The authors aimed to investigate the distribution of actionable surface targets TROP2, HER2, and FRα in endometrial carcinoma across various histologic, molecular, and genomic subgroups. Their findings revealed that TROP2 is widely expressed, while HER2 and FRα are predominantly found in high-grade serous tumors, particularly those with p53 abnormalities, suggesting the potential for biomarker-informed antibody-drug conjugate (ADC) therapies. The study highlights the need for targeted treatment strategies based on specific tumor characteristics.